Exacerbation frequency · people with bronchiectasis
28 days on/off antibiotic regimen showed no clear difference in exacerbation frequency compared with 28 days on/off placebo regimen (high certainty).
2 findings from 1 review
RR 0.92 [0.82, 1.02]
Studies not reported
High
no estimate extracted
Studies not reported
Low
Proportion of people with hospital admissions (from the emergency room) · acute exacerbations of chronic obstructive pulmonary disease
Intravenous magnesium sulfate + standard care may leads to lower proportion of people with hospital admissions (from the emergency… compared with placebo + standard care (low certainty).
1 finding from 1 review
Proportion of people requiring ventilatory support (NIV or assisted ventilation) · acute exacerbations of chronic obstructive pulmonary disease
It is very uncertain whether nebulised magnesium sulfate + standard care changes proportion of people requiring ventilatory support (NIV or assisted… compared with placebo + standard care (very low certainty).
1 finding from 1 review
Proportion of people with serious adverse events · acute exacerbations of chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Change in oxygen saturation (SaO2) · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Change in dyspnoea score · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
FEV1 · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Proportion of people requiring non‐invasive ventilation · acute exacerbations of chronic obstructive pulmonary disease
It is very uncertain whether intravenous magnesium sulfate + standard care changes proportion of people requiring non‐invasive ventilation compared with placebo + standard care (very low certainty).
1 finding from 1 review
Proportion of people with serious adverse events · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Length of hospital stay · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Change in oxygen saturation (SaO2) · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Change in dyspnoea score · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Proportion of people with hospital admissions (from the emergency room) · acute exacerbations of chronic obstructive pulmonary disease
It is very uncertain whether nebulised magnesium sulfate + standard care changes proportion of people with hospital admissions (from the emergency… compared with placebo + standard care (very low certainty).
1 finding from 1 review
Incidence of admissions to the ICU · acute exacerbations of chronic obstructive pulmonary disease
It is very uncertain whether nebulised magnesium sulfate + standard care changes proportion of people requiring ICU admission compared with placebo + standard care (very low certainty).
1 finding from 1 review
All‐cause mortality · adults with a confirmed diagnosis of mild COVID‐19, of whom only 10% (219/2132) participants had received ≥ 1 vaccination
Inhaled corticosteroids plus standard care showed no clear difference in all‐cause mortality compared with standard care (with or without placebo) (low certainty).
1 finding from 1 review
Admission to hospital or death · adults with a confirmed diagnosis of mild COVID‐19, of whom only 10% (219/2132) participants had received ≥ 1 vaccination
Inhaled corticosteroids plus standard care probably leads to lower admission to hospital or death compared with standard care (with or without placebo) (moderate certainty).
1 finding from 1 review
Resolution of symptoms · adults with a confirmed diagnosis of mild COVID‐19, of whom only 10% (219/2132) participants had received ≥ 1 vaccination
Inhaled corticosteroids plus standard care probably leads to higher symptom resolution: all initial symptoms resolved at day 14 compared with standard care (with or without placebo) (moderate certainty).
1 finding from 1 review
Time to symptom resolution · adults with a confirmed diagnosis of mild COVID‐19, of whom only 10% (219/2132) participants had received ≥ 1 vaccination
Inhaled corticosteroids plus standard care showed no clear difference in symptom resolution: duration to symptoms resolved compared with standard care (with or without placebo) (low certainty).
1 finding from 1 review